Literature DB >> 2265491

Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6.

M Mihara1, H Fukui, Y Koishihara, M Saito, Y Ohsugi.   

Abstract

We have previously reported that B cell abnormality in NZB/W F1 mice developed independently of thymus. Here we examined further whether B cells from NZB/W F1 mice respond to interleukin-6 (IL-6), a factor for terminal differentiation of B cells. When freshly isolated splenic B cells were incubated for 5 days in the presence of human IL-6, an increased production of both IgM and IgG, including anti-DNA antibody, was evident in NZB/W F1 mice; there was no increase in BALB/c mice. A magnitude of augmentation in IgG but not IgM production by IL-6 became more apparent in older NZB/W F1 mice. The increased immunoglobulin production seen with IL-6 was neutralized by treatment with rabbit anti-recombinant human IL-6 antibody. As B cells from athymic NZB/W F1 nude mice also responded to IL-6, it was suggested that B cells in NZB/W F1 mice differentiated into the IL-6-responding state in a thymus-independent manner. This B cell abnormality may be associated with the pathogenesis of autoimmune disease in NZB/W F1 mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2265491      PMCID: PMC1535487          DOI: 10.1111/j.1365-2249.1990.tb05485.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease.

Authors:  S Izui; P J McConahey; F J Dixon
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

2.  Studies of congenitally immunologic mutant New Zealand mice. III. Growth of B lymphocyte clones in congenitally athymic (nude) and hereditarily asplenic (Dh/+) NZB mice: a primary B cell defect.

Authors:  Y Ohsugi; M E Gershwin
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Surface and functional characteristics of B cells from lupus-prone murine strains.

Authors:  A N Theofilopoulos; R S Balderas; Y Gozes; J M Fidler; F T Liu; A Ahmed; F J Dixon
Journal:  Clin Immunol Immunopathol       Date:  1982-05

4.  The biological response modifier OK-432 (a streptococcal preparation) inhibits the development of autoimmune kidney disease in NZB/W F1 hybrid mice: possible involvement of tumor necrosis factor.

Authors:  M Mihara; Y Ohsugi
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

5.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

6.  Tolerance defects in New Zealand Black and New Zealand Black X New Zealand White F1 mice.

Authors:  K L McCoy; L Kendrick; T M Chused
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

7.  Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice.

Authors:  M W Steward; F C Hay
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

8.  Pathogenesis of the glomerulonephritis of NZB/W mice.

Authors:  P H Lambert; F J Dixon
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

9.  Induction of murine autoimmune disease by chronic polyclonal B cell activation.

Authors:  L Hang; J H Slack; C Amundson; S Izui; A N Theofilopoulos; F J Dixon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  B cell dependence on and response to accessory signals in murine lupus strains.

Authors:  G J Prud'homme; R S Balderas; F J Dixon; A N Theofilopoulos
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

View more
  12 in total

Review 1.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

2.  Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.

Authors:  H B Richards; M Satoh; J C Jennette; T Okano; Y S Kanwar; W H Reeves
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.

Authors:  M Mihara; Y Koishihara; H Fukui; K Yasukawa; Y Ohsugi
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

Review 4.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

5.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 6.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

7.  IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.

Authors:  M Mihara; N Takagi; Y Takeda; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

8.  Macrophage depletion decreases IgG anti-DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL-6.

Authors:  M E Alarcón-Riquelme; G Möller; C Fernández
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

9.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

Review 10.  Cytokine disturbances in systemic lupus erythematosus.

Authors:  Noam Jacob; William Stohl
Journal:  Arthritis Res Ther       Date:  2011-07-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.